Bintrafusp alfa for advanced, unresectable cervical cancer

featured image
Indications: Cervical cancer
Therapeutic Areas: Female Reproductive Cancer
Year: 2021

Bintrafusp alfa is in clinical development for the treatment of advanced, unresectable, or metastatic cervical cancer. Cervical cancer can be defined as advanced or metastatic when originates in the cervix and spreads to various other parts of the body. If cervical cancer is recurrent, metastatic or persistent, there are limited treatment options, with treatments usually aiming to alleviate symptoms and improve quality of life.
Bintrafusp alfa is a type of protein called an antibody, which can bind to a cancer-causing protein. Therefore, it activates the natural killer (NK) cell to attack the cancer cells. Bintrafusp alfa is administered by intravenous infusion (injection into the vein). If licensed, bintrafusp alfa would offer an additional treatment option for patients with advanced, unresectable and/or metastatic cervical cancer.